The efficacy of Plasma Rich in Growth Factors for the treatment of alveolar osteitis: A randomised controlled trial

Publication date: Available online 8 January 2018
Source:Journal of Oral and Maxillofacial Surgery
Author(s): Elizabeth M. King, Tanya L. Cerajewska, Matthew Locke, Nicholas CA. Claydon, Maria Davies, Nicola X. West
PurposeTo investigate the efficacy of plasma rich in growth factors (PRGF)® for the treatment of alveolar osteitis compared to a positive control Alvogyl®.MethodsThis single centre, single blind, randomised, two treatment, parallel study was conducted in a UK dental hospital. All healthy adults who presented with alveolar osteitis following tooth extraction over a 3 month period were invited to participate. Each socket was randomised and treated with one of two treatment modalities, a test treatment PRGF® or a positive control Alvogyl®. Following treatment, patients were reviewed at 3 and 7 days by a second clinician blinded to the treatment given. Outcome measures included pain, exposed bone, inflammation, halitosis, dysgeusia and quality of life assessment.Results38 patients with data from 44 sockets, 22 in the PRGF® group and 22 in the Alvogyl® group, were analysed. The PRGF® group demonstrated significantly faster bone coverage as well as significantly reduced inflammation and halitosis (p<0.05) compared to the control group receiving Alvogyl®. There was no significant difference for pain, quality of life measures or dysgeusia between the groups.ConclusionPRGF® predictably treated alveolar osteitis following tooth extraction compared to the conventional standard treatment of Alvogyl® which has been used for many years. PRGF could be considered as an alternative treatment for alveolar osteitis, and indeed appears to have significant advantages over Alvogel®.



http://ift.tt/2m7J8bK